

DIASORIN LAUNCHES THE LIAISON® *STREPTOCOCCUS PNEUMONIAE* AG ASSAY IN ALL COUNTRIES ACCEPTING THE CE MARK FOR THE DIAGNOSIS OF PNEUMOCOCCAL PNEUMONIA

THE LIAISON® *S.PNEUMONIAE* AG ASSAY:

- IS THE FIRST SOLUTION THAT COMES TO MARKET ALLOWING HIGH-THROUGHPUT QUALITATIVE DETECTION OF *S.PNEUMONIAE* ANTIGEN IN URINE SPECIMENS OF ADULT PATIENTS;
- DIAGNOSES AND DISCRIMINATES *PNEUMOCOCCAL PNEUMONIA* FROM OTHER LUNG INFECTIONS WITH A SIMPLE TEST METHOD;
- RUNS ON THE LIAISON® CLIA ANALYZERS;
- IS LAUNCHED IN ALL COUNTRIES ACCEPTING THE CE MARK.

Saluggia, Italy – September 9, 2024 - Diasorin (FTSE MIB: DIA) announces the launch of the new LIAISON® *S.pneumoniae* Antigen Immunodiagnostic Assay in all countries accepting the CE Mark, to aid in diagnosis of pneumococcal pneumonia infection, a community-acquired pneumonia (CAP).

Streptococcus pneumoniae, causes different types of acute, invasive, and non-invasive clinical infections, being the most frequently detected pathogen responsible for community-acquired pneumonia (CAP). Pneumococcal pneumonia is accompanied by *bacteraemia* in 10-30% of cases. The incidence of pneumococcal pneumonia is greatest at the extremes of age and in individuals with medical comorbidity. Determining pneumococcal etiology at an early stage of CAP encourages clinicians to administer a pathogen-directed therapy, such that prescribed broad-spectrum antibiotic treatments may be de-escalated.

The LIAISON® *S.pneumoniae* Ag assay is the first immunodiagnostic test on the market allowing high-throughput qualitative detection of *Streptococcus pneumoniae* antigen in urine specimens of adult patients with suspected pneumonia, and it provides a precise identification of the pneumococcal pneumonia infection.

The test is performed on the LIAISON® CLIA family of analyzers and offers a highly automated solution for the microbiology laboratory. With a simple test method, pneumococcal pneumonia can be identified in only 35 minutes, allowing timely and targeted antimicrobial treatment. Furthermore, the high inclusivity “91 serotypes identified” and full-automation approach empowers clinical decision-making and antibiotic stewardship.

“The launch of this new assay confirms our ability to position Diasorin as a specialty player, able to provide innovative solutions with a high medical value” commented Chen Even, Chief Commercial Officer of Diasorin. *“We are confident that our new assay will strongly contribute to discriminating etiological factors in severe community acquired pneumonia”*.

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasorin.com

For additional information, please contact:

Riccardo Fava
Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo
Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.com